A Study to Test How Well Different Doses of BI 754132 Are Tolerated in Patients With an Advanced Form of Age-related Macular Degeneration Called Geographic Atrophy

PHASE1TerminatedINTERVENTIONAL
Enrollment

18

Participants

Timeline

Start Date

July 26, 2019

Primary Completion Date

August 9, 2022

Study Completion Date

August 9, 2022

Conditions
Macular Degeneration
Interventions
DRUG

BI 754132

One single injection

Trial Locations (13)

19107

Mid Atlantic Retina, Philadelphia

28803

Western Carolina Retinal Associate PA, Asheville

30909

Southeast Retina Center, PC, Augusta

32503

Retina Specialty Institute, Pensacola

33880

Center for Retina and Macular Disease, Winter Haven

75231

Retina Foundation of the Southwest, Dallas

77401

Retina Consultants of Texas, Bellaire

90211

Retina-Vitreous Associates Medical Group, Beverly Hills

BS1 2LX

Bristol Eye Hospital, Bristol

L69 3GA

Royal Liverpool University Hospital, Liverpool

EC1V 2PD

Moorfields Eye Hospital, London

NE1 4LP

Royal Victoria Infirmary, Newcastle upon Tyne

SO16 6YD

Southampton General Hospital, Southampton

Sponsors
All Listed Sponsors
lead

Boehringer Ingelheim

INDUSTRY